Domenico Albano1,2, Alessandro Stecco3, Giuseppe Micci4, Luca Maria Sconfienza4,5, Stefano Colagrande6, Alfonso Reginelli7, Roberto Grassi7, Alessandro Carriero3, Massimo Midiri4, Roberto Lagalla4, Massimo Galia4. 1. Section of Radiological Sciences, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy. albanodomenico@me.com. 2. IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. albanodomenico@me.com. 3. Radiology Department, "Maggiore della Carità" Hospital, University of Eastern Piedmont, Novara, Italy. 4. Section of Radiological Sciences, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy. 5. Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy. 6. Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. 7. Section of Radiology and Radiotherapy, Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Abstract
PURPOSE: To perform a survey among all members of the Italian Society of Medical and Interventional Radiology (SIRM) to assess how whole-body MRI (WB-MRI) is performed in oncologic patients in Italy. METHODS: On March 2019, we administered an online poll to all SIRM members about their use of WB-MRI in 2018 asking 15 questions regarding oncologic indications, imaging protocol, use of contrast media, experience in WB-MRI, duration of scan time and reporting time. RESULTS: Forty-eight members participated to the survey. WB-MRIs/total MRIs ratio was 1%. Lymphoma was the most common indication (17/48, 35%), followed by myeloma and prostate cancer, with these three tumors representing the most common indication in 39/48 of cases (81%). WB-MRI acquisition time and reporting time were 46-60 min in 22/48 centers (46%) and 20-30 min in 19/48 (40%), respectively. WB-MRIs were mostly performed in 1.5T scanners (43/48, 90%), with surface coils (22/48, 46%) being preferred to Q-body (15/48, 31%) and integrated coils (11/48, 23%). Contrast media were injected in 22/48 of the centers (46%), mainly used for breast cancer (13/22, 59%). DWI was the most used sequence (45/48, 94%), mostly with b800 (27/48, 56%), b0 (24/48, 50%) and b1000 (20/48, 42%) values. In about half of cases, radiologists started evaluating WB-MRI non-contrast morphologic sequences, then checking DWI and post-contrast images. CONCLUSION: WB-MRI was mainly performed at 1.5T unit, with lymphoma, myeloma and prostate cancer having been the most common indications. The extreme variability in the choice of imaging protocols and use of contrast agents demonstrates the need of a standardization of WB-MRI application in clinical practice.
PURPOSE: To perform a survey among all members of the Italian Society of Medical and Interventional Radiology (SIRM) to assess how whole-body MRI (WB-MRI) is performed in oncologic patients in Italy. METHODS: On March 2019, we administered an online poll to all SIRM members about their use of WB-MRI in 2018 asking 15 questions regarding oncologic indications, imaging protocol, use of contrast media, experience in WB-MRI, duration of scan time and reporting time. RESULTS: Forty-eight members participated to the survey. WB-MRIs/total MRIs ratio was 1%. Lymphoma was the most common indication (17/48, 35%), followed by myeloma and prostate cancer, with these three tumors representing the most common indication in 39/48 of cases (81%). WB-MRI acquisition time and reporting time were 46-60 min in 22/48 centers (46%) and 20-30 min in 19/48 (40%), respectively. WB-MRIs were mostly performed in 1.5T scanners (43/48, 90%), with surface coils (22/48, 46%) being preferred to Q-body (15/48, 31%) and integrated coils (11/48, 23%). Contrast media were injected in 22/48 of the centers (46%), mainly used for breast cancer (13/22, 59%). DWI was the most used sequence (45/48, 94%), mostly with b800 (27/48, 56%), b0 (24/48, 50%) and b1000 (20/48, 42%) values. In about half of cases, radiologists started evaluating WB-MRI non-contrast morphologic sequences, then checking DWI and post-contrast images. CONCLUSION: WB-MRI was mainly performed at 1.5T unit, with lymphoma, myeloma and prostate cancer having been the most common indications. The extreme variability in the choice of imaging protocols and use of contrast agents demonstrates the need of a standardization of WB-MRI application in clinical practice.
Entities:
Keywords:
Cancer; Diffusion-weighted imaging; Gadolinium; Magnetic resonance imaging; Whole-body imaging
Authors: Thomas C Kwee; Taro Takahara; Reiji Ochiai; Kazuhiro Katahira; Marc Van Cauteren; Yutaka Imai; Rutger A J Nievelstein; Peter R Luijten Journal: Eur J Radiol Date: 2009-04-28 Impact factor: 3.528
Authors: Giuseppe Petralia; Anwar R Padhani; Paola Pricolo; Fabio Zugni; Marco Martinetti; Paul E Summers; Luigi Grazioli; Stefano Colagrande; Andrea Giovagnoni; Massimo Bellomi Journal: Radiol Med Date: 2018-11-14 Impact factor: 3.469
Authors: Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo Journal: Infect Agent Cancer Date: 2021-07-19 Impact factor: 2.965
Authors: Francesca Iacobellis; Donatella Narese; Daniela Berritto; Antonio Brillantino; Marco Di Serafino; Susanna Guerrini; Roberta Grassi; Mariano Scaglione; Maria Antonietta Mazzei; Luigia Romano Journal: Diagnostics (Basel) Date: 2021-05-30
Authors: Domenico Albano; Giuseppe Micci; Caterina Patti; Federico Midiri; Silvia Albano; Giuseppe Lo Re; Emanuele Grassedonio; Ludovico La Grutta; Roberto Lagalla; Massimo Galia Journal: Diagnostics (Basel) Date: 2021-05-31